Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Sep;33(9):1563–1568. doi: 10.1128/aac.33.9.1563

Effect of 2'-nor-cyclic GMP against guinea pig cytomegalovirus infection.

Z H Yang 1, H L Lucia 1, R L Tolman 1, R J Colonno 1, G D Hsiung 1
PMCID: PMC172703  PMID: 2554800

Abstract

Cyclic phosphate derivative of DHPG, 2'-nor-cGMP [9-[(2-hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]-guani ne phosphate-oxide] was evaluated for activity against guinea pig cytomegalovirus (GPCMV) infection in cultured guinea pig embryo cells and in guinea pigs. By virus yield reduction and plaque reduction assays, 2'-nor-cGMP was demonstrated to be 15- to 20-fold more potent against GPCMV infection than its parental drug DHPG. The selectivity index of 2-nor-cGMP was 110, which was 10-fold higher than that of DHPG. In cultured cells, 2'-nor-cGMP attained maximal antiviral activity when added to the cells within 12 h postinfection. In the studies on GPCMV infection in guinea pigs, 2'-nor-cGMP administered subcutaneously once daily (5 mg/kg per day) for 8 days, starting 24 after virus inoculation, significantly suppressed GPCMV infectivity titers in the blood, spleen, lung, and salivary gland during acute infection (10 days postinfection) as compared with sham-treated infected animals. A greater reduction of GPCMV infectivity titers in the salivary gland was noted during chronic infection (i.e., 24 days postinfection). Clinically, splenomegaly and peripheral lymphocytosis were significantly modified as compared with the sham-treated animals (P less than 0.05). The drug, administered at this dosage, was reasonably tolerated by the guinea pigs and showed clinical benefit.

Full text

PDF
1563

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balfour H. H., Jr, Bean B., Mitchell C. D., Sachs G. W., Boen J. R., Edelman C. K. Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution. Am J Med. 1982 Jul 20;73(1A):241–248. doi: 10.1016/0002-9343(82)90099-7. [DOI] [PubMed] [Google Scholar]
  2. Betts R. F. Cytomegalovirus infection in transplant patients. Prog Med Virol. 1982;28:44–64. [PubMed] [Google Scholar]
  3. Bia F. J., Griffith B. P., Fong C. K., Hsiung G. D. Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis. 1983 Mar-Apr;5(2):177–195. doi: 10.1093/clinids/5.2.177. [DOI] [PubMed] [Google Scholar]
  4. Biron K. K., Fyfe J. A., Stanat S. C., Leslie L. K., Sorrell J. B., Lambe C. U., Coen D. M. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8769–8773. doi: 10.1073/pnas.83.22.8769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chachoua A., Dieterich D., Krasinski K., Greene J., Laubenstein L., Wernz J., Buhles W., Koretz S. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med. 1987 Aug;107(2):133–137. doi: 10.7326/0003-4819-107-2-133. [DOI] [PubMed] [Google Scholar]
  6. Chou S. W., Dylewski J. S., Gaynon M. W., Egbert P. R., Merigan T. C. Alpha-interferon administration in cytomegalovirus retinitis. Antimicrob Agents Chemother. 1984 Jan;25(1):25–28. doi: 10.1128/aac.25.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Duke A. E., Smee D. F., Chernow M., Boehme R., Matthews T. R. In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine against cytomegaloviruses. Antiviral Res. 1986 Aug;6(5):299–308. doi: 10.1016/0166-3542(86)90025-2. [DOI] [PubMed] [Google Scholar]
  8. Fong C. K., Cohen S. D., McCormick S., Hsiung G. D. Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Antiviral Res. 1987 Jan;7(1):11–23. doi: 10.1016/0166-3542(87)90035-0. [DOI] [PubMed] [Google Scholar]
  9. Fong C. K., Lucia H., Bia F. J., Hsiung G. D. Histopathologic and ultrastructural studies of disseminated cytomegalovirus infection in strain 2 guinea pigs. Lab Invest. 1983 Aug;49(2):183–194. [PubMed] [Google Scholar]
  10. Freitas V. R., Smee D. F., Chernow M., Boehme R., Matthews T. R. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother. 1985 Aug;28(2):240–245. doi: 10.1128/aac.28.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Griffith B. P., Hsiung G. D. Cytomegalovirus infection in guinea pigs. IV. Maternal infection at different stages of gestation. J Infect Dis. 1980 Jun;141(6):787–793. doi: 10.1093/infdis/141.6.787. [DOI] [PubMed] [Google Scholar]
  12. Griffith B. P., Lucia H. L., Bia F. J., Hsiung G. D. Cytomegalovirus-induced mononucleosis in guinea pigs. Infect Immun. 1981 May;32(2):857–863. doi: 10.1128/iai.32.2.857-863.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Keay S., Bissett J., Merigan T. C. Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. J Infect Dis. 1987 Dec;156(6):1016–1021. doi: 10.1093/infdis/156.6.1016. [DOI] [PubMed] [Google Scholar]
  14. Laskin O. L., Cederberg D. M., Mills J., Eron L. J., Mildvan D., Spector S. A. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med. 1987 Aug;83(2):201–207. doi: 10.1016/0002-9343(87)90685-1. [DOI] [PubMed] [Google Scholar]
  15. Laskin O. L., Stahl-Bayliss C. M., Kalman C. M., Rosecan L. R. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis. 1987 Feb;155(2):323–327. doi: 10.1093/infdis/155.2.323. [DOI] [PubMed] [Google Scholar]
  16. Lucia H. L., Griffith B. P., Hsiung G. D. Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs. Intervirology. 1984;21(3):141–149. doi: 10.1159/000149512. [DOI] [PubMed] [Google Scholar]
  17. Macher A. M., Reichert C. M., Straus S. E., Longo D. L., Parrillo J., Lane H. C., Fauci A. S., Rook A. H., Manischewitz J. F., Quinnan G. V., Jr Death in the AIDS patient: role of cytomegalovirus. N Engl J Med. 1983 Dec 8;309(23):1454–1454. doi: 10.1056/NEJM198312083092312. [DOI] [PubMed] [Google Scholar]
  18. Meyers J. D., McGuffin R. W., Bryson Y. J., Cantell K., Thomas E. D. Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis. 1982 Jul;146(1):80–84. doi: 10.1093/infdis/146.1.80. [DOI] [PubMed] [Google Scholar]
  19. O'Donnell J. J., Jacobson M. A., Mills J. Development of cytomegalovirus (CMV) retinitis in a patient with AIDS during ganciclovir therapy of CMV colitis. N Engl J Med. 1987 Jun 18;316(25):1607–1608. doi: 10.1056/NEJM198706183162516. [DOI] [PubMed] [Google Scholar]
  20. Quinnan G. V., Jr, Masur H., Rook A. H., Armstrong G., Frederick W. R., Epstein J., Manischewitz J. F., Macher A. M., Jackson L., Ames J. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA. 1984 Jul 6;252(1):72–77. [PubMed] [Google Scholar]
  21. Shanley J. D., Morningstar J., Jordan M. C. Inhibition of murine cytomegalovirus lung infection and interstitial pneumonitis by acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1985 Aug;28(2):172–175. doi: 10.1128/aac.28.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shepp D. H., Dandliker P. S., de Miranda P., Burnette T. C., Cederberg D. M., Kirk L. E., Meyers J. D. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985 Sep;103(3):368–373. doi: 10.7326/0003-4819-103-3-368. [DOI] [PubMed] [Google Scholar]
  23. Tolman R. L., Field A. K., Karkas J. D., Wagner A. F., Germershausen J., Crumpacker C., Scolnick E. M. 2'-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity. Biochem Biophys Res Commun. 1985 May 16;128(3):1329–1335. doi: 10.1016/0006-291x(85)91086-1. [DOI] [PubMed] [Google Scholar]
  24. Wade J. C., Hintz M., McGuffin R., Springmeyer S. C., Connor J. D., Meyers J. D. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med. 1982 Jul 20;73(1A):249–256. doi: 10.1016/0002-9343(82)90100-0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES